By demonstrating the positive regulation of HuR on osteogenesis and the formation of HuR‐positive SGs in osteoblasts, this study highlights HuR and its SGs as potential therapeutic targets for age‐related bone loss. The gene discussed is ELAVL1; the disease is age.